[Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients].

Su L, Meng FS, Tang YQ, Wen Q, Liu YS, Tang LQ, Duan PK, Luo RJ

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue1 Mar 2009Cited by 8 (Europe PMC)

PMID19278583PepBankPUB-19278583

Publisher pageAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment raised monocyte HLA-DR expression versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 raised an immune marker (HLA-DR) compared with standard care.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD14+ monocyte HLA-DR expression
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
After treatment, peripheral blood CD14ww+ monocyte HLA-DR expression and the ratio of CD4(+)IFN-gamma (+)/CD4(+) IL-4(+) increased significantly in the treatment group (both P<0.05), with serum IL-6, IL-10 levels and APACHE II scores all reduced remarkably (all P<0.05). The values showed significant…
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858301
02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment raised the Th1/Th2 ratio versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 raised the Th1/Th2 immune cell ratio compared with standard care.
Peptide
Thymosin alpha-1
Outcome
IncreaseTh1/Th2 cytokine ratio (CD4+IFN-gamma+/CD4+IL-4+)
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
After treatment, peripheral blood CD14ww+ monocyte HLA-DR expression and the ratio of CD4(+)IFN-gamma (+)/CD4(+) IL-4(+) increased significantly in the treatment group (both P<0.05), with serum IL-6, IL-10 levels and APACHE II scores all reduced remarkably (all P<0.05). The values showed significant…
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858302
03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment lowered serum IL-6 versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 lowered IL-6 compared with standard care.
Peptide
Thymosin alpha-1
Outcome
DecreaseSerum IL-6
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After treatment, peripheral blood CD14ww+ monocyte HLA-DR expression and the ratio of CD4(+)IFN-gamma (+)/CD4(+) IL-4(+) increased significantly in the treatment group (both P<0.05), with serum IL-6, IL-10 levels and APACHE II scores all reduced remarkably (all P<0.05). The values showed significant…
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858303
04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment lowered serum IL-10 versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 lowered IL-10 compared with standard care.
Peptide
Thymosin alpha-1
Outcome
DecreaseSerum IL-10
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After treatment, peripheral blood CD14ww+ monocyte HLA-DR expression and the ratio of CD4(+)IFN-gamma (+)/CD4(+) IL-4(+) increased significantly in the treatment group (both P<0.05), with serum IL-6, IL-10 levels and APACHE II scores all reduced remarkably (all P<0.05). The values showed significant…
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858304
05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment lowered APACHE II scores versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 lowered illness severity scores compared with standard care.
Peptide
Thymosin alpha-1
Outcome
DecreaseAPACHE II score
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Intensive care and hospital outcomes · Whole body
Source sentences
Summary
After treatment, peripheral blood CD14ww+ monocyte HLA-DR expression and the ratio of CD4(+)IFN-gamma (+)/CD4(+) IL-4(+) increased significantly in the treatment group (both P<0.05), with serum IL-6, IL-10 levels and APACHE II scores all reduced remarkably (all P<0.05). The values showed significant…
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858305
06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment lowered the MODS development rate to 21% versus 47% with control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 lowered multiple organ dysfunction (21% versus 47% with standard care).
Peptide
Thymosin alpha-1
Outcome
DecreaseMODS development rate
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Intensive care and hospital outcomes · Whole body
Measurements
MODS rate
21%
treatment group
MODS rate
47%
control group
Source sentences
Summary
The MODS development rate in the treatment group was much lower than that of control group (21% vs. 47%, P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858306
07HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment shortened mechanical ventilation to 6.08 days versus 8.23 days with control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 shortened ventilator use (6.08 days versus 8.23 days with standard care).
Peptide
Thymosin alpha-1
Outcome
DecreaseLength of mechanical ventilation
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Intensive care and hospital outcomes · Whole body
Measurements
MV duration
6.08 days
treatment group
MV duration
8.23 days
control group
Source sentences
Summary
the length of use of MV was significantly reduced [(6.08+/-2.46) days vs. (8.23+/-3.47) days, P<0.05].
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858307
08HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment did not change the duration of infection versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 did not change infection duration compared with standard care.
Peptide
Thymosin alpha-1
Outcome
No significant changeInfection duration
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
There was no difference in the infection duration and length of ICU stay (both P>0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858308
09HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment did not change the length of ICU stay versus control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 did not change ICU stay compared with standard care.
Peptide
Thymosin alpha-1
Outcome
No significant changeLength of ICU stay
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Intensive care and hospital outcomes · Whole body
Source sentences
Summary
There was no difference in the infection duration and length of ICU stay (both P>0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858309
10HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In septic patients, ulinastatin plus thymosin alpha1 added to conventional treatment lowered 28-day mortality to 20% versus 33% with control.
In plain wordsIn septic patients, a regimen of ulinastatin and thymosin alpha1 lowered 28-day deaths (20% versus 33% with standard care).
Peptide
Thymosin alpha-1
Outcome
Decrease28-day mortality
Study
n = 242
Comparator
Conventional treatment (control)
Outcome group
Mortality · Whole body
Measurements
28-day mortality
20%
treatment group
28-day mortality
33%
control group
Source sentences
Summary
The mortality rate on 28 days in the treatment group was much lower than that in control group (20% vs. 33%, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and forty-two septic patients admitted to Guangzhou General Hospital of Guangzhou Military Command intensive care unit (ICU) during 2004.10-2008.6 were included, and they were randomly divided into treatment group (128 cases) and control group (114 cases).
Summary · context
The treatment group received conventional treatment plus immuno-modulation therapy including ulinastatin (first 200 kU injection intravenous twice a day for 4 days and 100 kU for another 6 days) and thymosin alpha1 (1.6 mg subcutaneous twice a day for 4 days, followed by 1.6 mg per day subcutaneous for another 6 days).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.